Aptevo Therapeutics Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Aptevo Therapeutics (APVO) Tops Q2 EPS by 3c
August 9, 2019 9:02 AM EDTAptevo Therapeutics (NASDAQ: APVO) reported Q2 EPS of ($0.30), $0.03 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $7.36 million versus the consensus estimate of $7.04 million.
Second Quarter 2019 Highlights
Achieved 32% increase in year-over-year IXINITY net revenue in the first half of 2019 through continued expansion of the patient base for IXINITYLaunched a new, more desirable 3,000 IU assay for IXINITY providing advantages for Hemophilia B patients and our channel partnersCompleted dosing in a Phase 1 clinical trial of APVO210 designed to evaluate single ascending doses (SAD) in healthy... More